bioavailability is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-05-31. Numbers and descriptions here follow the published literature rather than marketing material.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small-molecule REV-ERB agonist | Not a hormone or natural product |
| Primary targets | REV-ERBα and REV-ERBβ | Nuclear receptors involved in circadian and metabolic regulation |
| Appearance | White to off-white solid | Typical for purified research samples |
| Solubility | Soluble in DMSO and ethanol; low water solubility | Laboratory solubility depends on solvent and purity |
| Common synonyms | SR9009; Stenabolic | Stenabolic is a colloquial name, not a formal chemical name |
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
=== Explosives === Guncotton CE/TNT Nobel 808 plastic explosive Nobel 851 plastic explosive Nobel 852 plastic explosive PE2 plastic explosive SX2 sheet explosive PE3 plastic explosive PE3A plastic explosive PE4 plastic explosive - Both as individual sticks and as a slab charge (L3A1) No. 1 Mk 3-6 6 Inch Beehive Demolition Charge No. 2 Mk 1 General Wade Arched Demolition Charge No. 3 Mk 1 Hayrick Demolition Charge No. 11 Mk 1 Beehive Demolition Charge No. 14 Mk 1 Hayrick Demolition Charge - Both as individual charges and as part of the L1A1 Necklace Charge kit Bangalore torpedo No. 1 Baby Viper Mine Clearing Line Charge
==== Commander of the Order of the British Empire (CBE) ==== Military Division Royal Navy Captain Paul Branscombe, . Captain William Keith Hutchison. Captain Keith Frank Read. Army Major General Cedric Norman George Delves, , (485712), late The Devonshire and Dorset Regiment. Brigadier Kevin John Watson Goad, , (472543), late Royal Army Ordnance Corps. Colonel (Acting Brigadier) Keith Skempton (487055), late The Cheshire Regiment. Colonel (Acting Brigadier) Albert Edward Whitley, , (495259), late Corps of Royal Engineers. Royal Air Force Group Captain Roger Hubert Beazley, , (Retired). Group Captain George William Gibson, (Retired). Air Commodore Ernest William Tyack. Civil Division John Edwin Adshead. For services to the National Training Awards and to Vocational Training. Nicholas Kenneth Alston, Assistant Secretary, Ministry of Defence. Michael Day Beaumont, . For political and public service. Arthur John Armstrong Bell. For political and public service. Alastair John Bellingham, Professor of Haematology, King's College Hospital School of Medicine and Dentistry. For services to Medicine and to the Royal College of Pathologists. Professor Sushantha Kumar Bhattacharyya, Professor of Manufacturing Systems Engineering, University of Warwick. For services to Industry and to Technology. John David Stuart Brown, . For political and public service. Christopher John Skidmore Burd. For services to the Forestry Industry. David Thomas Burke, Expert Special Adviser on the Environment, Department of the Environment. David Adam Cairns, Music Critic, The Sunday Times.
==== 2026 Iran war ==== Kiggans has strongly supported the Trump administration in the 2026 Iran war, also known as Operation Epic Fury. Kiggans stated in March 2026 that the goals of the war include "destroying Iran's ballistic missile capability, destroying their navy, and destroying their ability to have nuclear weapons." In June 2026, Kiggans voted against a war powers resolution that would have limited the president's ability to wage war in Iran without congressional consent.
In doing so, Zita assured herself that in death, she and her husband would remain by each other's side. When the procession of mourners arrived at the gates of the Imperial Crypt, the herald who knocked on the door during the traditional "admission ceremony" introduced her as Zita, Her Majesty the Empress and Queen.
=== Other transport uses === GR footpath, a class of long-distance trail in western Europe Toyota GR engine, a petrol automotive engine series Green Line (Washington Metro), United States Capital Region Berliet GR, a range of heavy-duty trucks
Sources: en.wikipedia.org
=== Short-term effects === Insufflating (snorting) cocaine commonly causes increased mucus production due to irritation and inflammation of the nasal passages. This irritation leads to symptoms such as a runny nose, nasal congestion, and excessive or thickened mucus. Acute exposure to cocaine has many effects on humans, including euphoria, increases in heart rate and blood pressure, and increases in cortisol secretion from the adrenal gland. In humans with acute exposure followed by continuous exposure to cocaine at a constant blood concentration, the acute tolerance to the chronotropic cardiac effects of cocaine begins after about 10 minutes, while acute tolerance to the euphoric effects of cocaine begins after about one hour. With excessive or prolonged use, the drug can cause itching, fast heart rate, and paranoid delusions or sensations of insects crawling on the skin. Cocaine can induce psychosis characterized by paranoia, impaired reality testing, hallucinations, irritability, and physical aggression. Cocaine intoxication can cause hyperawareness, hypervigilance, psychomotor agitation, and delirium. Consumption of large doses of cocaine can cause violent outbursts, especially by those with preexisting psychosis. Acute exposure may induce arrhythmia, including atrial fibrillation, supraventricular tachycardia, ventricular tachycardia, and ventricular fibrillation. Acute exposure may also lead to angina, heart attack, and congestive heart failure.
RNA editing (also RNA modification) is a molecular process through which some cells can make discrete changes to specific nucleotide sequences within an RNA molecule after it has been generated by RNA polymerase. It occurs in all living organisms and is one of the most evolutionarily conserved properties of RNAs. RNA editing may include the insertion, deletion, and base substitution of nucleotides within the RNA molecule. RNA editing is relatively rare, with common forms of RNA processing (e.g. splicing, 5'-capping, and 3'-polyadenylation) not usually considered as editing. It can affect the activity, localization as well as stability of RNAs, and has been linked with human diseases. RNA editing has been observed in some tRNA, rRNA, mRNA, or miRNA molecules of eukaryotes and their viruses, archaea, and prokaryotes. RNA editing occurs in the cell nucleus, as well as within mitochondria and plastids. In vertebrates, editing is rare and usually consists of a small number of changes to the sequence of the affected molecules. In other organisms, such as squids, extensive editing (pan-editing) can occur; in some cases the majority of nucleotides in an mRNA sequence may result from editing. More than 160 types of RNA modifications have been described so far. The discovery of RNA modifications that result in the suppressing of immunogenicity of therapeutic mRNA led to their eventual adoption for COVID mRNA vaccines, and was recognized with the 2023 Nobel Prize in Physiology or Medicine to Katalin Karikó and Drew Weissman.
=== Pharmacodynamics === Esmodafinil has about 3-fold lower affinity for the dopamine transporter (DAT) compared to armodafinil or modafinil (Ki = 780 nM, 2,500 nM, and 2,300 nM, respectively). It showed about 2-fold lower potency than armodafinil and about 1.5-fold higher potency than modafinil as a dopamine reuptake inhibitor (DRI) in vitro (IC50Tooltip half-maximal inhibitory concentration = 8,700 nM, 4,000 nM, and 13,000 nM, respectively). Both enantiomers of modafinil preferentially bind to the DAT in an inward facing conformation that is associated with atypical DRI profiles. Esmodafinil was about 1.4- to 1.5-fold more potent than modafinil or armodafinil in substituting for cocaine in rodents. Esmodafinil and armodafinil have been said to have approximately equipotent pharmacological effects but differing pharmacokinetics. Esmodafinil has been researched for the treatment of cocaine addiction. Like armodafinil, esmodafinil attenuates the effects of cocaine by occupying the dopamine transporter. While doing so, esmodafinil increases dopamine levels in the nucleus accumbens to a lesser extent than cocaine. However, the short elimination half-life of esmodafinil has been cited as reason to investigate armodafinil as a cocaine addiction treatment instead.
== Medical training and career == Though born in Oklahoma City, Wilson grew up in Whittier, California. He completed his undergraduate degree in biology from California State University, Fullerton in 1974 and a master's degree in molecular biology and biochemistry from University of California, Irvine in 1977. He received his doctor of medicine degree from University of California, San Diego in 1984. The early part of his career saw him completing residency at the Mayo Clinic and taking professor and research roles at various universities. He served as a professor and Chair of the Department of Ophthalmology at the University of Washington in Seattle from 1998 to 2003, and was named Grace E. Hill Endowed Chair in Vision Research. Since 2003, he has been professor of ophthalmology and staff cornea and refractive surgeon at the Cleveland Clinic in Ohio, and he has served as the cornea and refractive fellowship director there 2006-2017. Wilson is the inventor of topical losartan treatment for corneal scarring/fibrosis. Wilson's laboratory studying corneal wound healing was funded by the National Eye Institute and the U.S. Department of Defense from 1993 to 2025.
Sources: en.wikipedia.org
=== Major neuroendocrine axes === Oxytocin and vasopressin (also called anti-diuretic hormone), the two neurohypophysial hormones of the posterior pituitary gland (the neurohypophysis), are secreted from the nerve endings of magnocellular neurosecretory cells into the systemic circulation. The cell bodies of the oxytocin and vasopressin neurons are in the paraventricular nucleus and supraoptic nucleus of the hypothalamus, respectively, and the electrical activity of these neurons is regulated by afferent synaptic inputs from other brain regions. By contrast, the hormones of the anterior pituitary gland (the adenohypophysis) are secreted from endocrine cells that, in mammals, are not directly innervated, yet the secretion of these hormones (adrenocorticotrophic hormone, luteinizing hormone, follicle-stimulating hormone, thyroid-stimulating hormone, prolactin, and growth hormone) remains under the control of the hypothalamus. The hypothalamus controls the anterior pituitary gland via releasing factors and release-inhibiting factors; these are substances released by hypothalamic neurons into blood vessels at the base of the brain, at the median eminence. These vessels, the hypothalamo-hypophysial portal vessels, carry the hypothalamic factors to the anterior pituitary, where they bind to specific receptors on the surface of the hormone-producing cells. For example, the secretion of growth hormone is controlled by two neuroendocrine systems: the growth hormone-releasing hormone (GHRH) neurons and the somatostatin neurons, which stimulate and inhibit GH secretion, respectively.
In patients with mildly elevated serum prolactin levels, secondary causes such as pituitary adenomas can be ruled out Elevated prolactin blood levels are typically assessed in women with unexplained breast milk secretion (galactorrhea) or irregular menses or infertility, and in men with impaired sexual function and milk secretion. If high prolactin levels are present, all known conditions and medications which raises prolactin secretion must be assessed and excluded for diagnosis. After ruling out other causes and prolactin levels remain high, TSH levels are assessed. If TSH levels are elevated, hyperprolactinemia is secondary to hypothyroidism and treated accordingly. If TSH levels are normal, an MRI or CT scan is conducted to assess for any pituitary adenomas. Although hyperprolactinemia is often uncommon in postmenopausal women, prolactinomas detected after menopause are typically macroadenomas. While a plain X-ray of the bones surrounding the pituitary may reveal the presence of a large macroadenoma, small microadenomas will not be apparent. Magnetic resonance imaging (MRI) is the most sensitive test for detecting pituitary tumors and determining their size. MRI scans may be repeated periodically to assess tumor progression and the effects of therapy. Computed Tomography (CT scan) is another indicator of abnormalities in pituitary gland size; it also gives an image of the pituitary, but is less sensitive than the MRI.
We are more and more coming to the awful conclusion that our Ra isotopes behave not like Ra, but like Ba... Perhaps you can come up with some fantastic explanation. We ourselves realize that it can't actually burst apart into Ba. Now we want to test whether the Ac-isotopes derived from the "Ra" behave not like Ac but like La.
Sources: en.wikipedia.org
It is a synthetic research compound that activates REV-ERB nuclear receptors. It is not an approved drug or dietary supplement. Most information comes from cell and animal studies.
It binds REV-ERBα and REV-ERBβ and changes transcription of metabolic genes. This can affect circadian rhythm, lipid use, and mitochondrial function. The full downstream effects are still under study.
No. Some rodent studies show increased endurance, but controlled human trials are lacking. Claims about human performance are not established by published evidence.
Legality depends on the country and the intended use. In many places it is not approved as a medicine and may be sold only as a research chemical. Importation or possession can be restricted, and sports organizations prohibit it.